Eli Lilly & Co. (LLY): Breast Cancer Drug Failure a Big Blow Amid Generic Threats

Published October 1, 2013

Eli Lilly & Co. (LLY): Breast Cancer Drug Failure A Big Blow Amid Generic Threats

Filed under: drug treatment program statistics

As the statistics show, the breast cancer market is 10 times bigger than stomach cancer, and hence the investors displeasure. Shares of Lilly fell … Lilly does not plan to submit an application to regulatory authorities for ramucirumab in the first …
Read more on iStockAnalyst (press release)

Tuesday's line-ups, official game notes, updated statistics vs. the Detroit Tigers

Filed under: drug treatment program statistics

Rainiers pitcher Forrest Snow has been suspended 50 games by major league baseball for a second positive test for a drug f abuse of the Minor League Drug Prevention and Treatment Program. Unlike the major league testing program which focuses only on …
Read more on TheNewsTribune.com (blog)

NPS Pharmaceuticals, Inc. (NPSP): NPS Pharmaceuticals' Management …

Filed under: drug treatment program statistics

The NewsMakers pipeline is also robust with more than 225 unpartnered programs that should be of interest to pharma business development and licensing professionals. These assets include more than 140 programs in the clinic. The quality of the 2013 …
Read more on Seeking Alpha